YOLOv11 performed best in a single-center comparison using augmented clinical photographs to detect and grade nipple injuries, but the study did not establish clinical benefit.

You plug in your controller, load into a ranked match, and within thirty seconds you’re dead from a shot that should have been physically impossible. In 2026, the opponent on the other end may not be ...

Ultralytics is the company behind YOLO, an open-source computer vision model used for tasks including detection, segmentation ...

An AI Wildlife-Crossing Alert System for Forest Roads Using Arduino UNO Q is a solar-powered edge-AI safety system designed ...

While Large Language Models (LLMs) like ChatGPT generate clever text and code on screen, a "next big wave" is hitting the ...

A benchmark study found that EDGI-YOLO improved mAP@0.5 by 3.94 percentage points over YOLOv8n on NEU-DET while reducing ...

Christopher Groux is a Testing Methodologies Manager, editor, writer and accessibility advocate. Before joining the Forbes Health team, he covered Accessibility at Reviewed and gaming at Inverse and ...

BioVision Lock is an intelligent security system that introduces a two-stage authentication mechanism by combining AI-based ...

Hello. We are Idein, a company that creates the technology and systems necessary to make AI useful in the real world, such as ...

Intrusion detection systems (IDS) and anomaly detection techniques are critical components of modern cybersecurity, enabling the identification of malicious activities and system irregularities in ...

Basel, 7 October 2026 - An international research team has reported new results from the first clinical cohort of blind people treated with an optogenetic therapy for advanced retinitis pigmentosa.

A gene therapy makes surviving retinal ganglion cells light-sensitive, allowing blind patients to detect objects using stimulating goggles. Five years after a landmark result in one patient, the first ...